openPR Logo
Press release

Generic Oral Liquid Drug Dosage Forms Evolving as Competitors Seek Opportunities

03-07-2017 11:10 AM CET | Health & Medicine

Press release from: Greystone Research Associates

(Amherst, NH) – The generic oral liquid dosage form drug segment is a rapidly evolving and fluid environment that has been a challenge to decision makers attempting to map strategies for success in this segment. Generic drugs are re-shaping the pharmaceutical industry, and the pace of activity shows no signs of slowing.

There are currently 309 distinct APIs for which there is at least one approved generic oral liquid dosage form ANDA. These 309 APIs account for 1,083 approved ANDAs. Including all approved doses, the current universe of generic oral liquid dosage forms consists of 1,283 unique solution, suspension and syrup products. These products are marketed and supplied by 282 companies. Competition among the various drug and therapeutic classes is uneven, with the top eight segments accounting for a disproportionate level of activity and revenue. Understanding the underlying factors affecting business performance is key to attaining financial targets.

As competition among generics suppliers for new products accelerates and would-be ANDA filers become increasingly aggressive in attempting to identify future opportunities, their ANDA filing strategies have come to reflect this. It’s is no longer uncommon for the owners of brand drug NDAs to find a list of tentative ANDA approvals in the FDA queue as their patent and/or exclusivity protection comes to an end.

The provisions of the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments) which govern the generic drug approval process give 180 days of marketing exclusivity to certain generic drug applicants. The 180-day generic drug exclusivity provision is one component of the complex patent listing and certification process, which also provides for a 30-month stay on generic drug approvals while certain patent infringement issues are litigated. So-called P (iv) filings are now routine for most brand drugs, requiring NDA holders to decide on a legal strategy to protect their brand often many years before existing patents for their products are due to expire.

Generic oral liquid dosage forms are detailed in a new and comprehensive report researched and written by Greystone Research Associates. Generic Oral Liquid Dosage Forms: Products, Markets, Players and Outlook analyzes generic oral solution, suspension and syrup products and the indications and therapeutic classes in which they compete. The report includes analysis of competitive factors, ANDA filing strategies, market growth trends and strategic and economic factors, and provides assessments of the market presence of sector participants.

More information is available at http://www.greystoneassociates.org



Source: Greystone Research Associates

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Contact:

Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020
www.greystoneassociates.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Generic Oral Liquid Drug Dosage Forms Evolving as Competitors Seek Opportunities here

News-ID: 458937 • Views: 246

More Releases from Greystone Research Associates

Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration
Antibacterial Treatments that don’t Rely on Antibiotics Winding their way thro …
(Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors. A microorganism can possess a wide array of virulence factors. They may only express these virulence factors when
3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Mi …
(Amherst, NH) – The promise of commercial microneedle drug delivery has been on the horizon for more than a decade. Like other compelling medical device innovations such as noninvasive glucose monitoring, the potential of the technology has yet to be realized due to the inability to solve the issues of reliable product performance from unit to unit and across a wide user population. To fully address the unmet need these technologies
Analysis of the Oncology Drug Pipeline Reveals Evolving Therapy Correlations and …
(Amherst, NH) – The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from

All 5 Releases


More Releases for NDA

PharmSource - CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance - …
PharmSource - CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance - 2017 Edition Where's your place in the CMO hierarchy? Find out in the CMO industry's authoritative analysis of manufacturing of NDA approvals. This CMO scorecard was compiled through hundreds of professional hours of research and analysis, and is presented in a 40-page report with over 30 graphs and tables. Only CMO Scorecard enables the CMO industry to benchmark its performance
Network Data Analytics (NDA) Market - Technology Advances, Trends and Forecast 2 …
Recent research and the current scenario as well as future market potential of "Network Data Analytics (NDA) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026" globally. Data analytics (DA) is the procedure of exploring various data sets so as to carry out detailed analysis of the available information, with the help of specialized software and systems. Data analytics techniques and technologies are widely used in
PharmSource-CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance-2018
This report is the 8th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs. Reasons to buy: This 43-page report gives important, expert insight you won’t find in any other source. 28 tables and figures throughout the report illustrate major points and trends.
Nuclear Decommissioning 2018 Global Market Key Players - AECOM, Areva Group, Bab …
Nuclear Decommissioning Market 2018  Wiseguyreports.Com Adds “Nuclear Decommissioning – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2023” To Its Research Database. Description:  This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Nuclear Decommissioning industry. This report splits Nuclear Decommissioning market
CMO Scorecard Market: Outsourcing of NDA Approvals and CMO Performance
Latest industry research report on: CMO Scorecard Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Find out in the CMO industrys authoritative analysis of manufacturing of NDA approvals. This CMO scorecard was compiled through hundreds of professional hours of research and analysis, and is presented in a 40-page report with over 30 graphs and tables. Only CMO Scorecard enables the CMO industry to benchmark its
CMO Scorecard Review: CMO Performance & Outsourcing of NDA Approvals 2017
Recently, Market Research Hub (MRH) has added a fresh report which focuses on the CMO industry’s authoritative analysis of manufacturing of NDA approvals. The research report focusing on the CMO Scorecard and is titled as, “PharmSource - CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance - 2017 Edition”. This CMO scorecard was assembled through hundreds of professional hours of research and analysis, and is comprised in a 40-page report. Request